File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Nebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker

TitleNebivolol: An endothelium-friendly selective β 1- adrenoceptor blocker
Authors
Keywordsβ-blocker
chronic heart failure
hypertension
nitric oxide
reactive oxygen species
Issue Date2012
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/
Citation
Journal Of Cardiovascular Pharmacology, 2012, v. 59 n. 1, p. 16-21 How to Cite?
AbstractNebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics endow nebivolol, compared with conventional β-blockers, with a favorable hemodynamic profile for the treatment of hypertension, chronic heart failure, and possibly other cardiovascular diseases. Nebivolol is a racemic mixture of d- and l-isomers. Its β 1-antagonistic properties reside primarily with d-nebivolol although both isomers are capable of increasing the release of NO from the endothelium after binding to β 2- or β 3- adrenergic receptors. The latter action results in vasodilatation and reduced vascular resistance. Nebivolol also scavenges ROS in a receptor-independent manner by direct interaction with free radicals. By scavenging ROS nebivolol not only reduces oxidant stress but also augments NO bioavailability. The endothelial nitric oxide synthase -stimulating and ROS scavenging effects of nebivolol act synergistically to provide cardiovascular protection in addition to its β 1-antagonistic action. © 2012 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/146890
ISSN
2015 Impact Factor: 2.462
2015 SCImago Journal Rankings: 0.962
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China30770789
30870938
Hong Kong Research Grant Council (University of Hong Kong)777507M
Funding Information:

Supported in part by the National Natural Science Foundation of China Grant No. 30770789 and 30870938 and by the Hong Kong Research Grant Council (University of Hong Kong-777507M).

References

 

DC FieldValueLanguage
dc.contributor.authorGao, Yen_HK
dc.contributor.authorVanhoutte, PMen_HK
dc.date.accessioned2012-05-23T05:48:50Z-
dc.date.available2012-05-23T05:48:50Z-
dc.date.issued2012en_HK
dc.identifier.citationJournal Of Cardiovascular Pharmacology, 2012, v. 59 n. 1, p. 16-21en_HK
dc.identifier.issn0160-2446en_HK
dc.identifier.urihttp://hdl.handle.net/10722/146890-
dc.description.abstractNebivolol is a highly selective β 1-adrenoceptor blocker, which also stimulates endothelial nitric oxide synthase and scavenges reactive oxygen species (ROS). These characteristics endow nebivolol, compared with conventional β-blockers, with a favorable hemodynamic profile for the treatment of hypertension, chronic heart failure, and possibly other cardiovascular diseases. Nebivolol is a racemic mixture of d- and l-isomers. Its β 1-antagonistic properties reside primarily with d-nebivolol although both isomers are capable of increasing the release of NO from the endothelium after binding to β 2- or β 3- adrenergic receptors. The latter action results in vasodilatation and reduced vascular resistance. Nebivolol also scavenges ROS in a receptor-independent manner by direct interaction with free radicals. By scavenging ROS nebivolol not only reduces oxidant stress but also augments NO bioavailability. The endothelial nitric oxide synthase -stimulating and ROS scavenging effects of nebivolol act synergistically to provide cardiovascular protection in addition to its β 1-antagonistic action. © 2012 Lippincott Williams & Wilkins, Inc.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/en_HK
dc.relation.ispartofJournal of Cardiovascular Pharmacologyen_HK
dc.subjectβ-blockeren_HK
dc.subjectchronic heart failureen_HK
dc.subjecthypertensionen_HK
dc.subjectnitric oxideen_HK
dc.subjectreactive oxygen speciesen_HK
dc.subject.meshAdrenergic beta-1 Receptor Antagonists - administration and dosage - pharmacology - therapeutic use-
dc.subject.meshBenzopyrans - administration and dosage - pharmacology - therapeutic use-
dc.subject.meshEndothelium, Vascular - drug effects - enzymology - metabolism-
dc.subject.meshEthanolamines - administration and dosage - pharmacology - therapeutic use-
dc.subject.meshHeart Failure - drug therapy - metabolism-
dc.titleNebivolol: An endothelium-friendly selective β 1- adrenoceptor blockeren_HK
dc.typeArticleen_HK
dc.identifier.emailVanhoutte, PM: vanhoutt@hku.hken_HK
dc.identifier.authorityVanhoutte, PM=rp00238en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/FJC.0b013e3182073e27en_HK
dc.identifier.pmid21283024-
dc.identifier.scopuseid_2-s2.0-84855358922en_HK
dc.identifier.hkuros199412en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84855358922&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume59en_HK
dc.identifier.issue1en_HK
dc.identifier.spage16en_HK
dc.identifier.epage21en_HK
dc.identifier.isiWOS:000298669500003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridGao, Y=36865936300en_HK
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats